Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.
Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in innovative cancer treatment through deep thermotherapy specifically targeting the head and neck region. As an Erasmus MC spinoff, the company focuses on developing novel hyperthermia techniques to enhance cancer care, providing a promising approach to improve treatment outcomes for patients suffering from tumors in these areas.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.
Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.
CYTO365 is the manufacturer of RondelO multi inlet stopcock, which is sold as a component aimed to be integrated into IV-set to combat Drug Incompatibility due to parallel infusion.
Selio is a simple, effective and patent protected technology. The Selio prototype has been rigorously tested in the lab and in subsequent acute pre-clinical in vivo studies with very positive results.
Ganymed Robotics SAS, a medical device company, focuses on the development of robotics technologies for orthopedic surgeons. It develops a therapeutic device to enhance surgical precision in knee replacement surgery. The company was incorporated in 2018 and is based in Paris, France.
Restore Medical develops and provides a device-based therapy for congestive heart failure. It improves patient quality of life and reduce hospital readmission rates. Restore Medical's product, ContraBand, is a novel catheter-delivered implant in the pulmonary arteries for treatment of left ventricle failure, for patients with preserved right ventricle function. Restore Medical was founded in 2016 and is headquartered in Or Yehuda, Israel.
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Orixha has developped an innovative device for cooling patients within few minutes and thus improve their prognosis by using a dedicated liquid ventilator able to perform safe and efficient total liquid ventilation. This method consists in filling the lungs with liquid perfluorocarbons and due to the high gases solubility and the large pulmonary sufaces can use the lungs as heat exchanger.
Limula Biotech is a Swiss company specializing in the design and development of an automated system for manufacturing cell and gene therapies. The company has created a patented platform that enables the distributed production of genetically engineered cells directly at the patient's bedside, utilizing a patient's white blood cell sample. This fully closed bioreactor system minimizes human intervention during the manufacturing process while maintaining control over cell culture parameters. By facilitating on-site production in hospitals, Limula's technology aims to enhance the safety, accessibility, and efficiency of personalized gene therapies, ultimately reducing time, costs, and logistical challenges. Founded in 2018 and based in Lausanne, Switzerland, Limula Biotech is committed to revolutionizing the delivery of ex vivo gene-engineered cell therapies.
Synergia Medical SA, founded in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in the development of innovative neurostimulation medical devices. The company is focused on creating optoelectronic neurostimulators that utilize advanced materials, optical components, biosensors, and microelectronics. In particular, Synergia Medical aims to manufacture MRI-safe, implanted devices designed for treating drug-resistant epilepsy, with potential applications in other therapeutic areas. The company has achieved ISO13485 certification within a short period and has successfully developed and marketed an OEM external neurostimulator for motorized amputee prostheses. Supported by private investors and public research grants, Synergia Medical has rapidly expanded its team to include thirteen skilled professionals dedicated to advancing neurostimulation technology.
Methinks Software, founded in 2016 and based in Barcelona, Spain, specializes in developing artificial intelligence medical software focused on stroke diagnosis and treatment. Utilizing advanced techniques from Google's deep learning framework, TensorFlow, the company analyzes neuroimaging to provide timely and accurate diagnoses of brain-related diseases, particularly acute strokes. Its medical imaging platform enables rapid assessment from non-contrast CT scans, streamlining the diagnosis process and facilitating improved communication between radiologists, hospitals, stroke units, and healthcare professionals. By bypassing the need for contrast CT scans, Methinks aims to reduce time-to-treatment, ultimately enhancing clinical outcomes and patient care in emergency settings.
Qubit Pharmaceuticals, incorporated in 2020 and based in Paris, France, develops innovative technology aimed at enhancing pharmaceutical drug discovery. The company offers a drug discovery simulation platform that reduces the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, Qubit's platform conducts virtual screening and visualization to identify promising drug candidates. This approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.
Loci Orthopaedics Limited is a medical technology company based in Upper Newcastle, Ireland, focused on developing innovative solutions for orthopedic care. Established in 2017, the company specializes in the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, providing a less invasive and easier insertion method compared to existing surgical options. Loci Orthopaedics also emphasizes evidence-based designs in its products, aiming to address significant unmet clinical needs in orthopedic extremities.
Loci Orthopaedics Limited is a medical technology company based in Upper Newcastle, Ireland, focused on developing innovative solutions for orthopedic care. Established in 2017, the company specializes in the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, providing a less invasive and easier insertion method compared to existing surgical options. Loci Orthopaedics also emphasizes evidence-based designs in its products, aiming to address significant unmet clinical needs in orthopedic extremities.
Hy2Care BV is a business start-up of the University of Twente, the Netherlands. It is Hy2Care’s ambition to introduce into the market the first cure for Osteoarthritis, the injectable hydrogel.
Osteoarthritis is the 4th leading cause of mobility associated disability and affects more than 100 million patients in the Western world, who are all in need for an effective treatment.
It is the aim of Hy2Care to change the future for patients suffering from osteoarthritis.
Legacy Healthcare is a biopharma company focused on the development of oncology supportive care and dermatology drugs
Artiria Medical SA develops micro-actuated device to treat vascular diseases. Its products bring micromotion deep in the brain arteries, enabling a navigation and stroke treatment. It empowers catheters and guidewires. Artiria Medical SA was incorporated in 2019 and is based in Lausanne, Switzerland.
Nuclidium’s vision is to address the unmet need to detect and stage cancer more accurately so that treatment options for cancer patients and their long-term survival can be significantly improved.
Piomic is a developer of a portable, hand-held medical device designed to treat chronic wounds, specifically targeting chronic leg and foot ulcers. The device utilizes optical and magnetic stimulation technologies to promote wound healing, aiming to alleviate the significant burden posed by the estimated 50 million patients suffering from hard-to-heal wounds globally. Clinical studies have demonstrated that the treatment is safe, accelerates wound closure, reduces pain, and enhances the overall quality of life for patients. The device features a simple, single-button operation, allowing for seamless integration into various healthcare settings, including stationary facilities, ambulatory care, and home use. Through its innovative approach, Piomic seeks to improve patient outcomes and provide a more effective solution for managing chronic wounds.
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
Genetika+ is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Venari Medical Limited, founded in 2018 and based in Galway, Ireland, develops innovative medical devices aimed at treating chronic venous diseases (CVD). The company's flagship product, BioVena, employs the body's natural healing processes to provide a more effective and less invasive treatment option for conditions such as varicose veins and venous ulcers. Venari Medical seeks to address the significant gap in treatment, as only a small fraction of the 120 million individuals suffering from venous disease in the US and EU receive adequate care. Their technology not only offers a safer alternative to existing methods but also targets the underserved population of venous ulcer patients who currently rely on ineffective compression bandaging. By widening the indications for superficial venous ablation, Venari Medical aims to reduce the annual costs associated with venous ulcers, which total approximately $33 billion for insurers in these regions. The company's commitment to patient-centered solutions positions it to disrupt traditional treatment practices that have seen limited innovation in recent years.
Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.
Spartha Medical is a medical technology company focused on developing eco-friendly, invisible coatings designed for medical devices and consumer products to mitigate microbial and inflammatory risks. Utilizing natural biopolymers, the company’s innovative coatings possess antibacterial, antiviral, and anti-inflammatory properties, providing an effective solution for infection control. The technology relies on a patented method of supramolecular assembly, enabling precise control over the properties of the coatings based on specific applications. This approach allows for the creation of multifunctional and easy-to-apply surface treatments that help healthcare institutions maintain disease-free environments on medical devices.
Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.
GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.
Filterlex Medical Ltd. is a medical device startup based in Yokneam, Israel, focused on developing innovative solutions in the cardiovascular field. Established in 2015, the company is dedicated to creating advanced embolic protection devices aimed at minimizing the risk of stroke and other complications during catheter-based structural heart procedures. Their flagship device, CAPTIS, is designed for intuitive deployment and retrieval, providing full-body embolic protection by effectively deflecting, capturing, and removing embolic particles. The development of Filterlex's technology is rooted in a comprehensive understanding of existing products' limitations, addressing unmet needs within the medical community. The company is currently seeking seed funding to further advance its mission.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
VBL Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and immune-inflammatory diseases. Founded to address significant unmet medical needs, the company focuses on creating therapies that surpass the limitations of currently available options. Its clinical pipeline is built on two proprietary platform technologies that utilize the body’s natural physiological and genetic regulatory mechanisms. The lead candidate, VB-111, is a gene-based biologic targeting solid tumors, specifically for recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also advancing a program aimed at anti-inflammatory diseases, leveraging its Lecinoxoid platform technology.
VBL Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancer and immune-inflammatory diseases. Founded to address significant unmet medical needs, the company focuses on creating therapies that surpass the limitations of currently available options. Its clinical pipeline is built on two proprietary platform technologies that utilize the body’s natural physiological and genetic regulatory mechanisms. The lead candidate, VB-111, is a gene-based biologic targeting solid tumors, specifically for recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also advancing a program aimed at anti-inflammatory diseases, leveraging its Lecinoxoid platform technology.
Syntach develops a cardiac support device to improve the care of the rapidly-growing number of people with heart failure.
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce extracellular vesicles at a commercial scale in a GMP compliant way for pharmaceutical companies with applications in regenerative medicine and drug delivery. Extracellular vesicles that encompass exosomes, microvesicles, and apoptotic bodies are the tools used by cells to communicate with each other. EVerZom was founded in 2019 and is headquartered in Paris, Ile-de-France, France.
Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of RNAi therapies to treat illnesses where no other treatments have proven effective or ever existed.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in innovative cancer treatment through deep thermotherapy specifically targeting the head and neck region. As an Erasmus MC spinoff, the company focuses on developing novel hyperthermia techniques to enhance cancer care, providing a promising approach to improve treatment outcomes for patients suffering from tumors in these areas.
Qubit Pharmaceuticals, incorporated in 2020 and based in Paris, France, develops innovative technology aimed at enhancing pharmaceutical drug discovery. The company offers a drug discovery simulation platform that reduces the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, Qubit's platform conducts virtual screening and visualization to identify promising drug candidates. This approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.
ADVITOS GmbH is a medical technology company based in Munich, Germany, specializing in extracorporeal multiple organ support therapy products for hospitals. Founded in 2004, the company offers the ADVanced organ support treatment, which utilizes a unique method known as ADVOS to facilitate blood purification. This innovative approach allows for the simultaneous removal of water-soluble and protein-bound toxins from the liver, lungs, and kidneys, while also correcting metabolic and respiratory acidosis. The ADVOS system operates using standard dialysis accesses and flow rates, eliminating the need for gas exchangers for CO2 removal. This technology aims to enhance the treatment outcomes for patients suffering from liver and kidney failure.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
SepTec is developing and commercializing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect pathogens in whole blood.
Developer of non-invasive inhalers designed for the treatment of respiratory disorders. The company's device generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, creating multiple momentary dilating forces that gently pry open the collapsed airways, enabling doctors to treat chronic obstructive pulmonary disease by smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.
Developer of non-invasive inhalers designed for the treatment of respiratory disorders. The company's device generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, creating multiple momentary dilating forces that gently pry open the collapsed airways, enabling doctors to treat chronic obstructive pulmonary disease by smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.
SepTec is developing and commercializing a revolutionary sample-to-answer sepsis diagnostic device that can rapidly detect pathogens in whole blood.
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
CarThera SAS specializes in the design and development of therapeutic ultrasound-based medical devices aimed at treating brain disorders. Founded in 2010 and headquartered in Paris, France, the company has developed innovative devices such as SonoProbe, which addresses conditions like brain tumors, epilepsy, metastases, and meningioma. Another key product is SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier, enhancing the delivery and concentration of therapeutic molecules for the treatment of primary brain tumors. Through these advancements, CarThera is focused on improving treatment outcomes for patients with serious neurological conditions.
CarThera SAS specializes in the design and development of therapeutic ultrasound-based medical devices aimed at treating brain disorders. Founded in 2010 and headquartered in Paris, France, the company has developed innovative devices such as SonoProbe, which addresses conditions like brain tumors, epilepsy, metastases, and meningioma. Another key product is SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier, enhancing the delivery and concentration of therapeutic molecules for the treatment of primary brain tumors. Through these advancements, CarThera is focused on improving treatment outcomes for patients with serious neurological conditions.
Resistell is a antibiotic resistance test.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Ilya Pharma AB is a biotechnology company based in Uppsala, Sweden, that specializes in developing biological drugs aimed at treating wounds in skin and mucosa. Founded in 2016, the company focuses on addressing both acute and chronic wounds, particularly those affecting individuals with diabetes. Ilya Pharma employs a unique approach by genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that enhance the healing process of skin injuries. Their innovative drug delivery system utilizes these bacteria as vectors to administer biological drugs directly at the wound site or within the gastrointestinal tract, facilitating accelerated healing in a cost-effective manner. The company’s research and development efforts are rooted in extensive scientific studies conducted at Uppsala University and the Swedish University of Agriculture.
FluoGuide A/S is a Copenhagen-based company that focuses on developing surgical solutions to enhance cancer treatment outcomes. Founded in 2018, the company is known for its product FG001, which utilizes a fluorophore that specifically binds to cancer cells expressing the urokinase receptor. By employing intelligent targeting techniques, FluoGuide aims to improve surgical precision, thereby reducing patient suffering and increasing the chances of successful treatment. Additionally, the company seeks to lower healthcare costs associated with cancer surgeries.
RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.
ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.
ADVITOS GmbH is a medical technology company based in Munich, Germany, specializing in extracorporeal multiple organ support therapy products for hospitals. Founded in 2004, the company offers the ADVanced organ support treatment, which utilizes a unique method known as ADVOS to facilitate blood purification. This innovative approach allows for the simultaneous removal of water-soluble and protein-bound toxins from the liver, lungs, and kidneys, while also correcting metabolic and respiratory acidosis. The ADVOS system operates using standard dialysis accesses and flow rates, eliminating the need for gas exchangers for CO2 removal. This technology aims to enhance the treatment outcomes for patients suffering from liver and kidney failure.
SOMAprobes S.L. develops healthcare technology for magnetic resonance imaging detection of bacterial pathogens at the onset of infectious disease. The company was incorporated in 2014 and is based in Donostia, Spain.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Plasmacure, located in Eindhoven, the Netherlands, focuses on developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. This innovative approach not only targets and eliminates bacteria but also promotes cell proliferation and enhances microcirculation. By addressing these critical factors, Plasmacure's technology helps healthcare professionals reduce the risk of amputation and improve the overall quality of life for patients suffering from chronic wounds.
EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware and software components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
MeMed Diagnostics Ltd. is a personalized diagnostics company established in 2009 and based in Tirat Carmel, Israel. The firm specializes in developing diagnostic solutions that focus on distinguishing between bacterial and viral infections to enhance patient care and reduce healthcare costs. Its flagship product, MeMed BV, is a test that analyzes patients' immune responses to differentiate between infection types. Additionally, the ImmunoDx platform combines proprietary biomarkers and algorithms to provide rapid and actionable insights for healthcare professionals, thereby addressing the challenge of antibiotic misuse, which is prevalent in healthcare systems worldwide. By accurately identifying the source of infection, MeMed's diagnostics aim to prevent inappropriate antibiotic prescriptions, mitigate the emergence of resistant bacterial strains, and ultimately improve treatment outcomes for infectious diseases.
Demeta S.A.S develops catalysts for green chemistry. The company offers Olefin Metathesis technology platform, which includes NexTene resins, a ruthenium catalysts; and Polymetallic Catalysis platform for oxidative cleavage of alkenes. The company was incorporated in 2011 and is based in Rennes, France.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
Trisol Medical Ltd is a company based in Yokneam, Israel, that specializes in the development of transcatheter tricuspid replacement valves. Established in 2016, it focuses on innovative solutions in the field of cardiac interventions, specifically targeting the treatment of tricuspid valve diseases. As a portfolio company, Trisol Medical is positioned within the medical technology sector, aiming to enhance patient outcomes through its advanced valve replacement technologies.
Trisol Medical Ltd is a company based in Yokneam, Israel, that specializes in the development of transcatheter tricuspid replacement valves. Established in 2016, it focuses on innovative solutions in the field of cardiac interventions, specifically targeting the treatment of tricuspid valve diseases. As a portfolio company, Trisol Medical is positioned within the medical technology sector, aiming to enhance patient outcomes through its advanced valve replacement technologies.
S-Biomedic is a Belgian biotech company specializing in live probiotic cosmetics designed to improve skin health. The company focuses on the skin microbiome, a complex ecosystem of beneficial and harmful bacteria that plays a crucial role in skin conditions such as acne, eczema, rosacea, and aging. S-Biomedic employs advanced modulation-based technology to selectively harness beneficial bacteria, creating products that promote the rebalancing of the skin microbiome. By utilizing the latest advancements in microbiology and dermatology, their offerings aim to restore healthy skin and address various dermatological concerns. Through this innovative approach, S-Biomedic provides therapeutic solutions in both the dermatology and cosmetic sectors, enhancing the overall health and beauty of the skin.
Demeta S.A.S develops catalysts for green chemistry. The company offers Olefin Metathesis technology platform, which includes NexTene resins, a ruthenium catalysts; and Polymetallic Catalysis platform for oxidative cleavage of alkenes. The company was incorporated in 2011 and is based in Rennes, France.
Antofénol is a post-harvest biocontrol company focused on reducing losses in agricultural produce, particularly in viticulture. The company specializes in the ecological eco-extraction of plant matter, utilizing innovative techniques such as microwaves, ultrasonics, vacuum, and mixing to develop tailored chemical compositions. Antofénol offers services that include eco-extraction, anti-fungal testing, and biochemical characterization, allowing harvesters to effectively protect fruits and vegetables from fungal and mold infestations. Through its approach, Antofénol aims to valorize viticultural waste while promoting sustainable agricultural practices.
Medicortex Finland is focused on developing a non-invasive, point-of-care diagnostic test for Traumatic Brain Injury (TBI) and concussions. Traditional diagnostic methods, such as CT and MRI scans, struggle to accurately diagnose mild TBIs. To address this, Medicortex is identifying brain injury biomarkers that can be detected from urine and saliva, with plans to incorporate these biomarkers into a hand-held diagnostic kit that provides rapid and reliable results without the need for medical professionals' interpretation. The company aims to collaborate with larger diagnostic firms for manufacturing and distribution. Its target customers include hospitals, emergency rooms, paramedics, military personnel, sports teams, pharmaceutical companies, and insurance providers. Medicortex has achieved significant milestones, including reaching Phase II clinical studies for its biomarker and receiving grant funding from the US Department of Defense, the European Union, and the Finnish Government.
Desentum Oy is a biopharmaceutical company based in Finland that focuses on developing innovative hypoallergenic vaccines aimed at treating various allergies, including those caused by pollen, pets, and certain food proteins. Established in 2011, Desentum employs a unique approach to allergy immunotherapy by altering the immune system's response to allergens, promoting tolerance instead of hypersensitivity. The company leverages its research into the molecular mechanisms behind allergic reactions to design effective vaccines that aim to provide long-term relief for patients suffering from allergic symptoms. By utilizing recombinant allergens modified to suppress histamine release during treatment, Desentum seeks to minimize adverse effects and streamline the desensitization process, ultimately addressing the social and economic burdens associated with allergies.